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Summary 
Efficient activation and regulation of the cellular immune response requires engagement of T 
cell accessory molecules as well as the antigen-specific T cell receptor. The lymphocyte func- 
tion-associated  antigen (LFA) 3 (CD58)/CD2  accessory pathway, one of the first discovered, 
has been extensively characterized in terms of structure and function of the CD2 molecule, which 
is present on all T lymphocytes and natural killer cells of the human immune system. The binding 
site of human CD2  for LFA-3 has been localized to  two epitopes  on one face of the first 
immunoglobulin (Ig)-like domain of this two-domain, Ig superfamily molecule. Human LFA-3 
is genetically linked and is 21% identical in amino acid sequence to CD2, suggesting  that this 
adhesive pair may have evolved from a single ancestral molecule. We have aligned the amino 
acid sequences of LFA-3 and CD2 and mutagenized selected amino acids in the first domain 
of LFA-3 that are analogous to those implicated in the binding site of CD2.  The data show 
that K30 and K34, in the predicted C-C' loop, and D84, in the predicted F-G loop of LFA-3, 
are involved in binding to CD2,  suggesting  that two complementary sites on one face of the 
first domain of each molecule bind to each other. 
H 
'uman LFA-3 (CD58)  is a widely distributed  cell sur- 
. face molecule capable of adhesion and signaling to T 
cells via its receptor, CD2 (1). LFA-3 is one of a number of 
"T cell accessory molecules" so called because LFA-3 engage- 
ment of CD2 on responder cells costimulates T cell prolifer- 
ation induced by anti-T cell receptor (TCR/CD3) antibody 
or antigen. The actions of accessory  molecules such as LFA-3 
are hypothesized to be required for the efficient generation 
of optimal antigen-specific responses. The timing and inten- 
sity of the antigen-specific and accessory signals is thought 
to determine the character of the T cell response, which can 
range from loss of ability to respond to antigen (anergy) to up- 
regulation of immune functions and proliferation (activation). 
LFA-3 and its counter-receptor CD2 belong to the Ig su- 
perfamily, as shown by nuclear magnetic resonance (NMR) 
and x-ray crystallography (2-4). Because LFA-3 and CD2 ex- 
hibit 21% amino acid homology and are closely linked ge- 
netically, it is considered likely that they share a common 
ancestral molecule. Interestingly, in mouse and rat, an LFA-3 
homologue has not been identified. In these species (but not 
in humans),  CD48,  also structurally related to CD2  and 
LFA-3, is a ligand for CD2 (5). CD2,  CD48,  and LFA-3 
are all located on human chromosome 1 (6). 
CD2 has been extensively studied at a molecular and func- 
tional level. Three functional epitopes on the human CD2 
molecule have been described and are recognized by mAbs 
Tl11, Tl12, and Tl13 (7). Pairs of mAbs such as Tl12 and 
Tl13 induce T cell proliferation. Similarly LFA-3 in conjunc- 
tion with certain  CD2-specific mAbs costimulates  T  cell 
proliferation.  Tl11,  which maps  to  the first  (most NH2- 
terminal) Ig domain of CD2, can block adhesion to LFA-3. 
An elegant study by Peterson and Seed (8), using saturation 
mutagenesis of human CD2 extracellular domains followed 
by expression and a double selection for epitope maintenance 
and loss of binding to LFA-3, localized the Tl11- and Tll~- 
binding epitopes to two sets of highly charged residues within 
the first domain. These CD2 epitopes corresponded closely 
to sets of residues involved in binding LFA-3, which they 
termed regions  I  and  II.  An NMR-derived structure for 
rat CD2 (2) further localized these sites three dimensionally 
to one face of the CD2 molecule. These results have since 
been confirmed and refined by a number of other studies 
(9-12). Rat and human CD2 are 40% identical in amino acid 
sequence, allowing  reasonably confident prediction of the 
human CD2  structure,  which was recently confirmed by 
NMR studies (4). 
To focus on areas of LFA-3 likely to be important in binding 
CD2, we hypothesized that the simplest scenario for evolu- 
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Volume 181  January 1995  429-434 tion of CD2 and LFA-3 from an ancestral molecule would 
be conservation of the active residues of the ancestral binding 
site. We aligned the amino acid sequence of the first domain 
of LFA-3 with that of CD2 to identify amino acid residues 
analogous to the active residues of CD2.  We then mutage- 
nized these residues, using plasmids encoding LFA-3/IgG1 
soluble fusion proteins as parental constructs.  The mutants 
were assayed for binding to CD2 and maintenance of LFA-3 
epitopes. We now report that a subset of the targeted residues 
are indeed important  for binding  of LFA-3 to  CD2. 
Materials  and Methods 
LFA-3 Domain 1 Modeling.  To construct a three-dimensional 
homology model of domain 1 of LFA-3, a procedure similar  to 
that described by Greet (13) was used with the aid of QUANTA 
software (Molecular Simulations, Inc., Sunnyvale, CA). The LFA-3 
amino acid sequence was aligned with that of human and rat CD2, 
and the alignment was refined manually so as to maximize the se- 
quence similarity matches of the presumed ~-strand segments. Coor- 
dinates for those segments were obtained from the rat CD2 struc- 
ture (3). The loops corresponding to insertions or deletions were 
built either by fragment search in the Brookhaven Protein Data 
Bank (Brookhaven, NY), or, in the case of those with one or two 
residues, were manually built and subjected  to energy minimiza- 
tion with CHARMm to obtain the minimal energy conformations 
(14). The whole model also was subjected to several cycles of energy 
minimization. 
Mutagenesis and Expression of LFA-3/Ig Plasmids.  LFA-3/Ig fu- 
sion constructs, previously described  (12), were used as parental 
constructs for the mutagenesis. Constructs encoding soluble LFA-3/ 
Ig fusion protein composed of LFA-3 domain 1 (previously described 
as LFA-3TIP, here called "D1/Ig"), or domain 1 +  2 (previously 
described as LFA-3FLIgG1,  here called "Dl+2/Ig") fused to the 
human IgG1 H  chain hinge, CH2 and CH3 regions, were sub- 
cloned into the transient expression plasmid CDM8 (15). Targeted 
mutants were made as described previously (16, 17). Sequence across 
the mutagenized region was determined for at least one isolate of 
each mutant,  and plasmids  were electroporated into COS7 cells 
for expression as described previously (18). Supematants containing 
secreted LFA-3/Ig were harvested 48-72 h after electroporation, 
and the quantity of fusion protein was normalized by ELISA by 
use of goat anti-human IgG serum (Jackson ImmunoResearch Labs, 
Inc., West Grove, PA) coated on Maxisorb plates (Nunc, Roskilde, 
Denmark) to capture, and HRP-conjugated goat anti-human IgG 
(Pierce Chemical Co., Rockford, IL) serum to detect, titered an- 
tigen, by use of standard  procedures. 
Adhesion Assay and Flow Cytometry.  Binding of mutant LFA-3/ 
Ig protein to CD2 was detected by "staining" CD2-expressing Jurkat 
cells with LFA-3/Ig-containing supernatants that had been quan- 
titatively normalized by dilution. Bound LFA-3/Ig was detected 
with PE-conjugated goat anti-human  IgGFc Fabs (Jackson  Im- 
munoResearch Labs, Inc.), followed by FACS  |  analysis (Becton 
Dickinson & Co., Mountain View, CA) of 10,000 cells. 
Binding to LFA-3-specific mAbs was assayed by ELISA. Super- 
natants were quantitatively normalized by dilution, incubated in 
96-well plates coated with anti-human IgG serum to capture LFA-3/ 
Ig, and washed. LFA-3-specific mAbs previously described (12, 19) 
were added at a maximum concentration of 10/~g/ml, titered by 
serial twofold dilution,  and detected with  horse radish  peroxi- 
dase-goat-anti-mouse IgG. The minimum dilution of mAb that 
gave maximal signal was used to calculate the percent binding to 
each mAb of each mutant, compared with the parental control su- 
pernatant. Polyclonal guinea pig serum also used in binding studies 
was made by immunizing with Freund's adjuvant plus recombinant 
soluble  (rs) LFAo3 (20). 
Results 
Design of Mutant Constructs.  Previously, it was shown that 
the first Ig-like domain of LFA-3 is surf/dent for binding to 
CD2 (12). The alignment shown in Fig.  1 was used to pre- 
dict residues of LFA-3 analogous to binding residues in CD2, 
which we hypothesized might participate in mutually com- 
plementary binding regions. Priority was given to region I 
LFA-3 residues (which, according to our hypothesis, would 
bind to region II of CD2) because we have previously shown 
that LFA-3/CD2 binding is most sensitive to mutations within 
CD2 region II (12), and because Tlll mAbs (to region II of 
CD2) block adhesion to LFA-3, while Tl12 mAbs do not. 
Construction, Expression,  and Assay of Mutant  Constructs. 
Mutant constructs were made by use of gapped-heteroduplex 
oligonucleotide-directed mutagenesis. After transfection into 
COS7 cells and collection of supernatants containing secreted 
soluble fusion protein, expression was assessed by ELISA by 
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Figure  1.  Alignment of LFA-3 with human (h) and rat (r) CD2 amino acid sequences, fl strands, determined from NMR and x-ray crystallographic 
analysis of rat CD2 as described in the text, are underlined and lettered a, b, c, c', etc. Human CD2 epitopes, which are required for binding of blocking 
mAb Tlll (Region II) and signaling mAb Tl12 (Region I) are indicated. Residues of CD2 implicated in binding to LFA-3 in other publications are 
indicated below the alignment (8-12). Residues mutagenized for this study are indicated above the alignment. Some were mutagenized in combination, 
whereas others were performed singly, as indicated in Fig. 2. 
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.
 use of anti-human  IgG1 polyclonal serum, which binds to 
the Ig Fc portion of the molecule,  in an area unaffected by 
the mutagenesis. Ability of mutants to bind to CD2 was de- 
termined by FACS  |  analysis of binding  to the T leukemia 
line Jurkat. Results are presented numerically in Table I and 
in  summary form  in  Fig.  2,  where constructs  displaying 
staining or binding  at a level >50%  of the wild-type level 
are indicated as  +,  10-50%  as  +/-,  and 0-10%  as  -. 
Replacement amino acids for the targeted residues were 
chosen with the goal of maintaining proper local folding of 
the protein (see below). The best substitution  for a partic- 
ular amino acid was difficult to predict, resulting in several 
attempts for many of the mutations in areas of particular in- 
terest. 
EIJitopes of LFA-3 Domain  1.  It is important  to distin- 
guish mutants that have lost CD2 binding  activity due to 
large-scale perturbations in structure From those that show 
effects limited  to contact residues. To identify  mutants ex- 
hibiting  improper folding of domain  1, we stained with a 
panel of mAbs representative of every known epitope of LFA-3 
within these domains, in addition to a guinea pig polyclonal 
serum, mAbs that map to domain 1 include blocking (i.e., 
able to block binding of LFA-3 to CD2) mAbs 7A6, TS2/9, 
1A3, and 1A2, and nonblocking mAbs 1C4 and PAK-1. Cross- 
blocking  studies have shown that mAbs  7A6,  TS2/9,  and 
1A3 bind to closely related epitopes, while 1A2,  1C4, and 
PAK-1 bind to distinct though somewhat  overlapping epi- 
topes  [(19); Chisholm,  P.,  and C.  Williams,  unpublished 
results). All of these epitopes were capable of being disrupted 
by mutations to linearly discontinuous areas of dom~n 1 (Table 
1 and Fig. 2), indicating that they recognize conformational 
epitopes and are sensitive to local denaturation caused by im- 
proper folding. Most of the mutants that retain these sensi- 
tive epitopes bind well to CD2, indicating that the substituted 
amino acid residues can support both proper folding and ligand 
binding. 
Mutations  That Conserve EpitoI~es But Diminish Binding to 
CD2.  The most informative mutants are those that retain 
sensitive epitopes but show diminished binding to CD2. LFA-3 
region I mutants #109, 94, and 84 implicate the two lysine 
residues K30 and K34,  located in the predicted C-C' loop 
of LFA-3, in binding  to CD2 (Table 1 and Fig. 2).  LFA-3 
residue K34  is analogous to the important K48  residue in 
region I of CD2, shown to be involved in both binding  of 
CD2 to LFA-3 (8) and in the functionally important epitope 
bound  by Tl12-1ike mAbs,  which are capable of costimu- 
lating  T  cell proliferation when present with mAb Tl13. 
When LFA-3 K34 was changed to A, binding to CD2 was 
lost, although  a panel of mAbs  specific for distinct LFA-3 
epitopes still bound, indicating that proper folding elsewhere 
in the molecule was maintained (Fig. 2).  The mutation  of 
K30 to A also diminished binding to CD2 without epitope 
loss, suggesting that, as in CD2, more than one charged res- 
idue on the face of the molecule is involved in formation of 
the binding site. These informative mutants were also made 
in DI+ 2/Ig and showed the same phenotype regarding loss 
of CD2 binding. 
Mutations  also were made in the predicted F-G loop of 
LFA-3, which is structurally analogous  to region II (func- 
tional  epitope  T11t)  of CD2.  The  mutation  D84  to  K 
resulted reproducibly in partial loss of binding  to CD2, al- 
though all epitopes were maintained. D84 of LFA-3 is analo- 
Amino acids changed:  Mutant #:t  Jurkat cell CD2  GP set 
K24E  M83t  +  + 
K24E  FLM83t  +  + 
K29KQKDK/RKQRDR  M109  + 
K29KQKDK/RKQRDR  FLM109  + 
K30A  M94  +/-  + 
K30A  FLM94  + 
K34A  M84  + 
K34A  FLM84  + 
$47A  FLM116  +  + 
$69A  FLM117  +  + 
OINK  M76  +/-  + 
T83DT/ADA  M96  +  + 
K87E  Ml10  +  + 
1.93A  FLM118  +  + 
Epitope loss muta'~ons: 
K29KQK/EKQE  M73  + 
K29KQK/AKOA  M93  + 
K30E  M74  + 
K34E  M75  + 
F46S/AA  M85  + 
Y54L/AA  M86  + 
D84A  M95  + 
K87A  M97  +/-  + 
7A6"  TS2/9" 
+ 
+  + 
+I'-  +I- 
+  + 
+  + 
+  + 
+/*  +/- 
+ 
+  + 
+  + 
+  + 
+  + 
+  + 
+  + 
+/-  +I- 
+I- 
+/-  +I- 
+I-  +/- 
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1A3"  1A2"  1C4  PAK-1 
+  +  +/-  + 
+  +  +  + 
+  +  + 
+/o  +  +  + 
+  +  +  + 
+  +  +  + 
+I-  +  +  + 
+  +  + 
+  +  +  + 
+  +  +  + 
+  +  +  + 
+  +  +  + 
+  +  +  + 
+  +  +  + 
+I-  +I-  +I-  +I- 
+I- 
+/-  +/- 
+  +/- 
+I-  +I-  +I-  +I- 
+I-  +I-  +I-  +I- 
Figure  2.  Summary of binding 
of  human  LFA-3/Ig  mutants  to 
CD2 and mAbs. Expression of each 
construct was normalized by ELISA 
with an anti-lgFc mAb, as described 
in Materials and Methods.  (*) Mu- 
tant  numbers  prefixed  with "M" 
were made with D1/Ig as the pa- 
rental construct,  while those  pre- 
fixed with "FLM" (for "full length 
mutant") were made with DI+ 2/Ig 
as the parental construct.  Binding 
to other mAbs and to Jurkat (CD2- 
bearing)  cells  was  calculated  as  a 
percentage  of parental  D1/Ig  or 
Dl+2/Ig binding, after correction 
for  expression  (see  Materials  and 
Methods).  Mutations  significantly 
reduced in binding to CD2 while 
maintaining most epitopes  are in- 
dicated in bold face type. See Table 
I for numerical values. +, 50-100%; 
_% 10-50%;  -, 0-10%  wild-type 
binding. Figure 3.  Hypothetical  model of  domain 1 of  LFA-3  showing proposed 
contacts with CD2. The crystal structure of rat CD2 domain 1 was used 
as a template for the generation of this three-dimensional model, with 
QUANTA protein homology modeling software used as described in 
Materials and Methods. The human CD2 domain 1 three-dimensional  struc- 
ture is very similar to that of the rat by NMR (4) and more recently by 
x-ray (21) analyses. 
gous to D78 of CD2;  it is predicted to protrude from the 
same face of the molecule as the highly charged basic residues 
of the C-C' loop, as shown in our hypothetical model (Fig. 
3). Other mutations we tested in this area  resulted in either 
unaffected binding to CD2 (T83DT/ADA and K87E) or loss 
of multiple epitopes,  indicating poor folding (D84A and 
K87A). 
In addition to mutations targeted to the predicted regions 
of binding,  we made mutations in areas not expected to be 
involved  in binding. All of  these either had no effect  on binding 
to CD2 (K24E, $47A, $69A, L93A) or perturbed folding 
as well as binding (F46S/AA, Y54L/AA). 
Discussion 
We have shown that charged residues in the predicted C-C' 
and F-G loops of LFA-3 domain 1 are involved in binding 
of LFA-3 to CD2. According to our alignment of the amino 
acid sequences of LFA-3, with its genetically linked ligand 
CD2,  these  LFA-3 residues are structurally analogous  to 
known binding residues of  CD2. The simplest way in which 
LFA-3 and CD2 molecules on apposing cells could interact 
is by mutually complementary binding sites (Fig. 3), such 
as is seen in crystal forms of  both rat and, very recently, human 
CD2  (3,  21). 
Because there are many examples of Ig superfamily adhe- 
sion molecules that exhibit homophilic (self-) binding (e.g., 
NCAM, PECAM, CEA, etc.), we and others have  hypothe- 
sized that CD2 and LFA-3 have  evolved after duplication of 
the gene for a single homophilic ancestral molecule (22, 23). 
Although it is not possible to test directly an evolutionary 
hypothesis, our results and the crystal forms mentioned above 
are indirectly supportive  of this view. 
The ability of anti-CD2 mAbs or soluble LFA-3 to costimu- 
late T cell proliferation in concert with anti-TCR/CD3 mAb 
stimulation  indicates that binding of LFA-3 to CD2 has a 
signaling as well as an adhesive function. Molecular dissec- 
tion of the well-conserved CD2 cytoplasmic domain defined 
separable portions involved in signaling and ligand avidity 
regulation,  confirming the signaling function (24, 25). The 
natural  affinity of the CD2/LFA-3 interaction  is relatively 
low [2  x  106 M-1 (26)], which would suggest that weak 
rather than strong adhesion may actually optimize perfor- 
mance of the molecule's accessory role. Although controver- 
sial, it has been reported that CD59 also binds CD2, thus 
potentially strengthening the APC-T cell interaction medi- 
ated via CD2 (9, 27). It may be easier than in cases of natu- 
rally strong adhesion to find or design a blocking molecule 
with higher affinity for CD2 than the natural ligand, LFA-3. 
Such a molecule could block both binding and signaling 
through the LFA-3/CD2 and potentially the CD59/CD2 
pathways, thus performing an immunosuppressive function. 
In summary, mutations in amino acids of  LFA-3 predicted 
to be analogous to the binding site of its close relative and 
coreceptor CD2 can reduce or abolish binding of LFA-3 to 
this coreceptor. The amino acids comprising these sites are 
(hypothetically, for LFA-3) part of the C-C' and F-G loops 
of the most NH2-terminal Ig-like domain of each molecule. 
Knowledge of these binding sites may aid in design of pep- 
tides or other small molecules that could block the LFA- 
3/CD2 pathway in a therapeutic  setting,  thus providing  a 
new immunosuppressive  agent. 
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